



**ECMOTOX Consortium: Guidelines**

**1. List of medications included in the ECMOTOX Consortium:**

- a. Beta blockers
- b. Calcium channel blockers
- c. Flecainide
- d. Bupropion
- e. Tricyclic Antidepressants
- f. Diphenhydramine
- g. Colchicine

Any other potential cardiotoxic exposure.

**2. Objectives:**

- a. Provide early consultation and collaboration to identify acutely poisoned patients who may benefit from ECMO therapy after a potentially life-threatening cardioactive drug ingestion.
- b. Assist healthcare providers, particularly in lower resource areas, to gain expedited access to an ECMO team and referral to an ECMO center.

**3. Triage information:**

Medication	Actual GPC triage dose	Lowest reported toxic dose <sup>1,2,3</sup>	Reported lethal dose <sup>1,2,3*</sup>
BB: Acebutolol	>24mg/kg or >1200mg	Adult: 600mg Children: >12mg/kg	Unknown
BB: Atenolol	>5mg/kg or >250mg	Adult: >200mg (5.3mg/kg) Children: 2mg/kg	Unknown
BB: Carvedilol	>1mg/kg or >80mg	Adult: >50mg Children: 0.5 mg/kg	Unknown
BB: Labetalol	>20mg/kg or >800mg	Adult: >400mg Children: >20mg/kg	Unknown

BB: Metoprolol	SR>12.5mg/kg or >500mg Other >4mg/kg or >500mg	Adult: >450mg IR, >400mg SR; Children: >2.5 mg/kg, >5 mg/kg SR	Unknown
BB: Nadolol	>5mg/kg or 640mg	Adult: >320 mg Children:>2.5 mg/kg	Unknown
BB: Propranolol	SR >10mg/kg or >480mg Other >5mg/kg or >480mg	Adult: >240 mg Child: >4 mg/kg IR, >5 mg/kg SR	>1g
BB: Sotalol	>8mg/kg or >320mg	Adult: 160mg Child: >4mg/kg	3.2g
CCB: Amlodipine	>0.3mg/kg	Adult: >10 mg Children: >0.2 mg/kg	Child: 0.9 to 4.1 mg/kg Adult: 70mg
CCB: Diltiazem	SR >6.5mg/kg or Other >5mg/kg	Adult: 360mg IR, 700mg SR Children: 5mg/kg	Adult: 360mg IR 240–360 mg SR
CCB: Nifedipine	SR >5mg/kg or No SR >3mg/kg	Adult: 600mg Children: 1.25 mg/kg	
CCB: Verapamil	SR >15mg/kg or No SR >16mg/kg	Adult: 160mg IR, 720mg SR Children: 5 mg/kg	Single PO adult dose fatalities in children
Flecainide	n/a	>400mg	500mg
Bupropion	>10mg/kg		>9g
Cyclic antidepressants A = amitriptyline I = imipramine D = desipramine Do = doxepin N= nortriptyline	>1.5mg/kg (all)	A/I/Do: >5mg/kg D/N: >2.5mg/kg	10-20mg/kg (all) 15mg/kg (A/I/D) 250mg (A/I)
Diphenhydramine	>8mg/kg	Adult: >1g Children: 10-15mg/kg	Adult:>20mg/kg Children: 11.6 mg/kg
Colchicine	n/a	0.5-0.8mg/kg	0.8mg/kg

Table 1: Current GPC referral guidelines; Lowest reported toxic dose and longest reported delay to onset of toxicity from single ingestions reported in the literature.

\*Most reported data is based on low quality evidence and should be used as guidance.

GPC= Georgia Poison Center, mg= milligram, kg= kilogram, hrs= hours, IR= immediate release, SR= sustained release, BB= beta blocker, CCB= calcium channel blocker

**4. Obtain the following information:**

- a. Medication ingested: dosage, formulation, amount, time of ingestion, co-ingestions
- b. Initial and last set of vital signs, including temperature
- c. Laboratory studies: point of care glucose level, CBC, CMP, serum lactic acid, troponin

- d. **Bedside or Point-of-Care US (POCUS) echocardiogram to assess ejection fraction**
- e. Medical interventions and ongoing therapies (*e.g.*, IVF, calcium, atropine, inotropes, vasopressors, high-dose insulin, mechanical interventions, positive pressure ventilation).

**5. Does the patient have any of the following potential indications for ECMO?**


- a. Refractory cardiogenic shock despite maximum medical management?
- b. Deemed by toxicologist to have concerning ingestion based on history:
  - i. Concerning ingestion within toxic or lethal dose range (Refer to Table 1)
  - ii. Co-ingestion of additional cardioactive medications (*e.g.*, CCB, BB, antidepressants)
  - iii. Evidence of end organ dysfunction (*e.g.*, acute renal failure, pulmonary edema, encephalopathy)
- c. Concerning history based on discussion with toxicology + cardiogenic shock requiring more than one inotrope/vasopressor
- d. Exclusion criteria:
  - i. Standard ECMO exclusion (see Emory ECLS guideline below)
  - ii. Inability to safely anticoagulated, age > 70 years old, life-limiting co-morbidities, multiple organ failures, aortic insufficiency
  - iii. Double home dose
  - iv. Single ingestion of immediate release product in an asymptomatic patient
  - v. If you identify an exclusion criterion in an ECMO candidate, please call ECMO Coordinator on-call for further discussion
  - vi. \*For patients <18 years old, please contact the CHOA transfer center at 404-785-7778

**6. Overall process:**


- a. Provider calls GPC.
- b. GPC identifies potential patient for ECMOTOX pathway and calls toxicology fellow and/or attending on call.
- c. GPC starts ToxSentry chart while toxicology fellow/attending discuss case with provider.
  - i. Determine if patient meets inclusion criteria for ECMOTOX pathway.
  - ii. Determine if patient meets exclusion criteria for ECMOTOX pathway.
- d. If the patient meets inclusion criteria, **SPI connects toxicology/ fellow** with on-call ECMO provider (Figure 1).
- e. ECMO provider will determine if patient appropriate for ECMO
  - i. Yes:
    - 1. GPC conference in Emory transfer center (Figure 1) (toxicologist, ECMO-provider, GPC, Emory transfer center, rural ED provider)
    - 2. ECMO team calls Emory transfer center
  - ii. No:

1. Provide standard treatment recommendations
  2. Provide plan for next steps if patient decompensates
- f. Alternative plan (call originates with Emory Transfer Center):
- i. Provider calls Emory ECMO team/Emory Transfer Center for potential ECMO
  - ii. Emory ECMO team/Emory Transfer Center recognizes potential cardiotoxin-induced ill patient and calls GPC
  - iii. GPC starts at step 6.c.
- g. Toxicology team will continue to follow at bedside on arrival to Emory Hospital (non-critical care floor or ICU)\*
- i. This guideline will be updated accordingly to include all ECMO centers with open beds/closest ECMO center as this information and collaboration becomes available.

Figure 1: ECMO criteria and referral process



## EM: VA ECMO Criteria and Cannulation After Cardiotoxic Drug Overdose



\*These instructions will only be used for EDs with the capability to cannulate for ECMO in the ED or has ECMO available in house

**References:**

<sup>1</sup>Micromedex (electronic version). IBM Watson Health; 2023. Accessed [06/20/2023]. <https://www.micromedexsolutions.com> .

<sup>2</sup> Wax PM, Erdman AR, Chyka PA, Keyes DC, Caravati EM, Booze L, Christianson G, Woolf A, Olson KR, Manoguerra AS, Scharman EJ, Troutman WG. beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43(3):131-46. PMID: 15906457.

<sup>3</sup>Olson KR, Erdman AR, Woolf AD, Scharman EJ, Christianson G, Caravati EM, Wax PM, Booze LL, Manoguerra AS, Keyes DC, Chyka PA, Troutman WG; American Association of Poison Control Centers. Calcium channel blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43(7):797-822. doi: 10.1080/15563650500357404. PMID: 16440509.

Date: July 21, 2023

Liz Rivera Blanco  
Medical Toxicology Fellow

Emily Kiernan, DO  
Medical Toxicologist



Accredited as a Regional Poison Center by the American Association of Poison Control Center